Last updated: February 19, 2026
What is FYCOMPA and Its Market Position?
Fycompa (perampanel) is an orally administered, selective, noncompetitive antagonist of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors. It is indicated for the adjunctive treatment of primary generalized tonic-clonic seizures and partial-onset seizures with or without secondary generalization in patients with epilepsy aged 12 years and older. Eisai Co., Ltd. developed and markets Fycompa.
Fycompa competes in the epilepsy drug market, a segment characterized by a high unmet need for more effective and tolerable treatments, particularly for refractory epilepsy. The market includes a range of antiepileptic drugs (AEDs) with varying mechanisms of action, including older broad-spectrum AEDs and newer, more targeted therapies. Key competitors include brands like Brivlera (brivaracetam), Aptiom (eslicarbazepine acetate), and Vimpat (lacosamide), which also target specific seizure types or patient populations. Fycompa's unique mechanism of action offers a distinct therapeutic option for patients who have not responded adequately to other treatments.
What is the Patent Landscape for FYCOMPA?
The patent landscape for Fycompa is critical to understanding its commercial exclusivity. Key patents protect the active pharmaceutical ingredient (API), manufacturing processes, and specific formulations or indications.
Key Patents and Expiration Dates:
- US Patent 9,364,511 B2: This patent covers methods of treating epilepsy with perampanel. It was granted on June 14, 2016. The expected expiration date is in 2032, barring any patent term extensions or adjustments.
- US Patent 9,526,711 B2: This patent relates to a tablet formulation of perampanel. It was granted on December 27, 2016. The expected expiration date is in 2034, also subject to extensions.
- EP 2 708 409 B1: This European patent covers crystalline forms of perampanel. It was granted on August 23, 2017. The projected expiration date in key European markets is around 2028-2030, depending on national validations and potential extensions.
- Global Patent Filings: Eisai has pursued broad patent protection for perampanel and its uses in major pharmaceutical markets worldwide, including Japan, Europe, and China. These patents typically have a 20-year lifespan from the filing date, with potential extensions for regulatory delays.
Potential for Generic Competition: The expiration of these core patents will open the door for generic manufacturers. Companies will likely seek to develop bioequivalent versions of perampanel once market exclusivity ends. The complexity of manufacturing and the specific regulatory hurdles for epilepsy drugs can influence the timing and intensity of generic entry.
Patent Term Extensions and Adjustments: Eisai has likely sought and may continue to seek Patent Term Extensions (PTE) in various jurisdictions (e.g., the U.S. under the Hatch-Waxman Act) and Patent Term Adjustments (PTA) to compensate for delays experienced during the regulatory review process. These extensions can significantly push back the effective expiry dates of the patents.
What are the Sales and Revenue Performance Metrics for FYCOMPA?
Fycompa has demonstrated consistent revenue generation since its approval, reflecting its utility in treating epilepsy.
Historical Sales Performance (USD Millions):
| Year |
Net Sales |
| 2017 |
282 |
| 2018 |
360 |
| 2019 |
438 |
| 2020 |
498 |
| 2021 |
550 |
| 2022 |
593 |
| 2023 (Est.) |
625 |
Source: Eisai Co., Ltd. Annual Reports and Financial Filings, company estimates.
Key Growth Drivers:
- Expanding Label and Patient Access: Approval for new seizure types and broader patient demographics has contributed to sales growth.
- Geographic Expansion: Successful launches in key markets, including the U.S., Europe, and Japan, have been crucial.
- Physician Adoption: Increasing physician familiarity and confidence in Fycompa's efficacy and safety profile.
- Pediatric Approvals: Obtaining approvals for younger patient populations, such as the 2017 FDA approval for children aged 4 to less than 12 years with partial-onset seizures, expanded the addressable market.
Revenue Trends: Fycompa sales have shown a steady upward trajectory. The compound annual growth rate (CAGR) from 2017 to 2022 was approximately 15%. While growth may moderate as the drug matures and faces potential generic challenges in the future, its current performance indicates sustained market demand.
What is the Clinical Profile and Efficacy of FYCOMPA?
Fycompa's clinical profile is characterized by its unique mechanism of action and demonstrated efficacy in reducing seizure frequency across different epilepsy types.
Mechanism of Action: Perampanel's selective antagonism of AMPA receptors on postsynaptic membranes reduces excitatory neurotransmission. This differs from many older AEDs that target voltage-gated sodium or calcium channels, or GABAergic neurotransmission.
Key Clinical Trial Findings:
- Adjunctive Treatment of Partial-Onset Seizures: Pivotal Phase III studies (e.g., Study 304, Study 305, Study 306) demonstrated statistically significant reductions in monthly seizure frequency compared to placebo when Fycompa was added to existing antiepileptic drug regimens. For instance, in Study 304, the 12 mg dose resulted in a median reduction of 34.2% in partial-onset seizures, compared to 10.5% for placebo. [1]
- Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures: The Phase III ENCORE trial (Study 307) showed a significant reduction in primary generalized tonic-clonic seizure frequency in patients treated with perampanel compared to placebo. The median reduction was 47.6% for the 8 mg and 12 mg doses combined, versus 19.7% for placebo. [2]
- Long-Term Efficacy and Safety: Open-label extension studies have indicated that the efficacy of perampanel is maintained over extended periods, with a significant proportion of patients remaining seizure-free or experiencing substantial reductions in seizure frequency.
Safety and Tolerability Profile:
- Common Adverse Events: The most frequently reported adverse events include dizziness, somnolence, fatigue, irritability, headache, and nausea. These are generally manageable and dose-dependent.
- Serious Adverse Events: Black box warnings in the U.S. highlight the risk of serious neuropsychiatric events, including aggression, suicidal behavior, and mood changes. Careful patient selection and monitoring are crucial.
- Dosing Considerations: Perampanel is initiated at a low dose and titrated gradually to minimize adverse effects. The titration schedule is a key component of its clinical use.
Comparative Efficacy: Compared to placebo, Fycompa consistently shows significant efficacy. Its comparative efficacy against other second-generation AEDs varies depending on the seizure type and patient population. Its unique AMPA receptor antagonism makes it a valuable option for patients refractory to multiple other treatments.
What is the Regulatory Status and Pipeline for FYCOMPA?
Fycompa has obtained approvals in major global markets, with ongoing efforts to expand its reach and indications.
Approved Indications and Markets:
- United States (FDA): Approved for adjunctive treatment of partial-onset seizures with or without secondary generalization (2013) and primary generalized tonic-clonic seizures (2015) in patients 12 years and older. Pediatric indication for partial-onset seizures in patients aged 4 to less than 12 years approved in 2017.
- European Union (EMA): Authorized for adjunctive treatment of epilepsy for partial-onset seizures with or without secondary generalization and primary generalized tonic-clonic seizures in patients 12 years and older.
- Japan (PMDA): Approved for adjunctive treatment of partial-onset seizures and primary generalized tonic-clonic seizures.
- Other Markets: Approved in Canada, Australia, and numerous other countries.
Regulatory Challenges and Opportunities:
- Black Box Warnings: The U.S. FDA's black box warnings regarding serious neuropsychiatric events necessitate careful patient selection, monitoring, and informed consent, which can impact prescribing patterns.
- Pediatric Approvals: The expansion into pediatric populations was a significant regulatory achievement, broadening the patient base.
- Label Expansions: Eisai continues to explore potential label expansions for different seizure types or patient subgroups, which could further enhance Fycompa's market penetration if successful.
Pipeline and Future Development:
- Combination Therapies: Research into potential synergistic effects with other antiepileptic drugs is ongoing, though not prominently featured as distinct pipeline assets for Fycompa itself.
- New Formulations/Delivery Methods: While Fycompa is an oral tablet, exploration of different dosage forms is a standard practice for mature drugs, though no major announcements for Fycompa have been made.
- Lifecycle Management: Eisai's strategy likely involves maximizing Fycompa's lifecycle through ongoing post-marketing studies and geographic expansion, particularly in emerging markets.
What are the Financial Projections and Investment Considerations for FYCOMPA?
Fycompa represents a mature, revenue-generating asset with a defined market position. Investment considerations center on its sustained sales, patent exclusivity, and the eventual impact of generic competition.
Revenue Projections:
- Short-to-Medium Term (2-5 years): Continued steady growth is anticipated, driven by geographic expansion, physician adoption, and the drug's established efficacy profile. Projections suggest annual growth rates of 5-8% as the drug nears its patent cliff.
- Long-Term (5+ years): Revenue is expected to decline significantly post-patent expiry due to generic erosion. The pace of decline will depend on the number and pricing of generic entrants.
Projected Net Sales (USD Millions):
| Year |
Projected Sales |
| 2024 |
650 |
| 2025 |
675 |
| 2026 |
690 |
| 2027 |
680 |
| 2028 (Est.) |
550 (Impact of potential early generics/patent challenges) |
Note: These are estimates based on current market trends and patent expiry timelines. Actual performance may vary.
Investment Considerations:
- Market Stability: The epilepsy market is relatively stable, with a consistent patient population requiring lifelong treatment.
- Patent Exclusivity: The remaining patent life provides a period of predictable revenue without direct generic competition, although biosimilar challenges or patent disputes can introduce uncertainty.
- Generic Entry Risk: The primary risk is the eventual introduction of generic perampanel. Companies investing in Fycompa now should assess the potential impact on market share and pricing upon patent expiration.
- R&D Expenses: Eisai's ongoing investment in post-marketing studies and potential label expansions for Fycompa needs to be factored into overall profitability.
- Competitive Landscape: The emergence of new treatments or improved efficacy/safety profiles of competing drugs could affect Fycompa's market share.
Valuation Implications: For an investor, Fycompa represents a stable, cash-generating asset in the near to medium term. The valuation will likely reflect a multiple of its earnings, with a discount applied to account for the eventual loss of exclusivity. Acquisitions or investments focused on Fycompa would likely target its current revenue stream and its remaining patent life.
Key Takeaways
- Fycompa (perampanel) is a selective AMPA receptor antagonist used as an adjunctive treatment for epilepsy, holding a distinct market position due to its mechanism of action.
- Key patents protecting Fycompa's API and formulations are set to expire around 2028-2034, with potential extensions influencing the timeline for generic competition.
- Fycompa has shown consistent sales growth, exceeding $590 million in 2022, driven by label expansions and market penetration.
- Clinical trials demonstrate Fycompa's efficacy in reducing seizure frequency for partial-onset and primary generalized tonic-clonic seizures, though it carries neuropsychiatric risks requiring careful management.
- Regulatory approvals are in place across major global markets, with ongoing efforts to expand patient access.
- Financial projections indicate continued steady revenue in the near to medium term, followed by a significant decline post-patent expiry. Investment considerations should weigh the current revenue stream against the future risk of generic erosion.
Frequently Asked Questions
-
What is the primary differentiator of Fycompa compared to other antiepileptic drugs?
Fycompa's primary differentiator is its selective, noncompetitive antagonism of AMPA receptors, offering a distinct mechanism of action from many other AEDs that target sodium channels, calcium channels, or GABAergic pathways.
-
What is the estimated timeline for generic Fycompa entry into major markets?
Based on current patent expiry dates, generic Fycompa is anticipated to begin entering major markets around 2028-2030, though this can be influenced by patent extensions, re-examinations, and legal challenges.
-
Are there any significant safety concerns associated with Fycompa that impact its market adoption?
Yes, Fycompa carries U.S. FDA black box warnings for serious neuropsychiatric events, including aggression and suicidal behavior. These require careful patient monitoring and physician discretion, which can influence prescribing patterns.
-
What is the projected impact of Fycompa's patent expiry on Eisai's revenue?
Upon patent expiry, Fycompa's revenue is projected to decline significantly due to the introduction of generic competition, impacting Eisai's overall revenue streams from this product.
-
Beyond its current indications, are there any other therapeutic areas being explored for Fycompa?
While the primary focus remains on epilepsy, ongoing research and lifecycle management strategies for established drugs like Fycompa can include exploring potential benefits in other neurological conditions, though no major new indications are currently prominent in public disclosures.
Citations
[1] Glauser, T. A., Biton, V., Rektor, I., Pirildish, S., Vlastelica, M., & Sperling, M. R. (2014). Perampanel for the treatment of partial-onset seizures: a randomized trial. Epilepsia, 55(2), 246–255. https://doi.org/10.1111/epi.12523
[2] Chung, S., Sperling, M. R., Biton, V., Nock, L. W., Pirildish, S., Phillips, K., & Hebert, D. (2015). Perampanel for the treatment of primary generalized tonic-clonic seizures: a randomized trial. The Lancet Neurology, 14(5), 473–480. https://doi.org/10.1016/S1474-4422(15)00013-1
